Showing 151-160 of 354 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Building Organotypic Vascularized Pancreatic Islets with Real-Time 4D Tracking of Engraftment and Vascular Maturation | The Regents of the University of California, Los Angeles | Chen Yuan Kam | Cures | 01-April-2026 to 31-March-2027 | $200,000.00 |
| Antigen-specific immunotherapies based on ignored ß-cell antigen determinants. | The Regents of the University of California, Los Angeles | Daniel Kaufman | Cures | 01-October-2024 to 30-September-2027 | $573,101.00 |
| Multiplex in vivo imaging of the dynamics of immune-mediated rejection of allogenic islet grafts | The Regents of the University of California, Los Angeles | Oluwatayo Ikotun | Cures | 01-February-2024 to 31-January-2027 | $749,996.25 |
| Prevascularized encapsulation platform with local immunosuppression for Islet transplantation | The Methodist Hospital Research Institute | Alessandro Grattoni | Cures | 01-August-2021 to 30-April-2027 | $692,000.00 |
| Investigation of novel local immunomodulating strategies to enhance islet transplantation for T1D | The Methodist Hospital Research Institute | Alessandro Grattoni | Cures | 01-July-2022 to 30-June-2027 | $962,995.99 |
| Tolerance inducing NanoLymph for in vivo generation of islet autoantigen-specific regulatory T cells | The Methodist Hospital Research Institute | Ying Xuan Chua | Cures | 01-April-2025 to 31-March-2027 | $200,000.00 |
| Defining the cell surface glycoproteome and glycome of human islets to enable single cell analysis of human β-cells | The Medical College of Wisconsin Inc. | John Corbett | Cures | 01-October-2022 to 30-June-2026 | $748,379.70 |
| Engineering hypoimmune cells for Type 1 Diabetes | The Jackson Laboratory | Paula Guallart | Cures | 01-May-2025 to 30-April-2028 | $1,498,415.83 |
| A prodrug system for targeted activation of small molecules in beta cells | The Brigham and Women’s Hospital, Inc. | Amit Choudhary | Cures | 01-February-2024 to 31-January-2027 | $2,250,000.00 |
| Expanding Access to T1D Care through the PEN-Plus Strategy | The Brigham and Women’s Hospital, Inc. | Gene Bukhman | Mission | 01-August-2024 to 31-July-2027 | $5,999,961.29 |